Home › Research › Treatments
MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease
Filippi M, Cecchetti G, Agosta F.. Current opinion in neurology, 2023-06-23
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Purpose of review Currently, three antibeta amyloid (Aβ) mAbs are approved or under examination in USA and in Europe for the treatment of patients with early Alzheimer's disease. The aim of this review is to summarize the role of MRI in the mandatory redefinition of dementia care. Recent findings Disease-modifying therapies require a reliable biological diagnosis of Alzheimer's disease. Structural MRI should be acquired at the beginning of the diagnostic process as a gateway before subsequent etiological biomarkers. MRI findings, indeed, may support a diagnosis of Alzheimer's disease or suggest alternative non-Alzheimer's disease conditions. Given the high risk/benefit ratio of mAbs and the impact of amyloid-related imaging abnormalities (ARIA), moreover, MRI will be crucial for the appropriate patient selection and safety monitoring. Ad-hoc neuroimaging classification systems of ARIA have been developed and continuous education of prescribers and imaging raters is prompted. MRI measures have been also assessed in clinical trials as potential markers of therapeutic efficacy; results, though, are controversial and still need clarification. Summary Structural MRI will play a crucial role in the upcoming era of amyloid-lowering mAbs against Alzheimer's disease, from the correct patient selection to the monitoring of adverse events and of disease progression.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Filippi, M., Cecchetti, G., & Agosta, F. (2023). MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease. Current opinion in neurology. https://doi.org/10.1097/wco.0000000000001177
Vancouver
Filippi M, Cecchetti G, Agosta F. MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease. Current opinion in neurology. 2023. doi:10.1097/wco.0000000000001177. PMID: 37382144.
BibTeX
@article{filippi2023-37382144,
author = {Filippi, M. and Cecchetti, G. and Agosta, F.},
title = {{MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease}},
journal = {Current opinion in neurology},
year = {2023},
doi = {10.1097/wco.0000000000001177},
pmid = {37382144},
url = {https://doi.org/10.1097/wco.0000000000001177}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- MRI measures have been also assessed in clinical trials as potential markers of therapeutic efficacy; results, though, are controversial and still need clarification.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 23 of the 58 points we could judge it on, which is 40 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current opinion in neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37382144) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 23 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 23 of the 58 points we could judge it on is 40 out of 100. |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.